medigraphic.com
Colegio de Medicina Interna de México.

2019, Number 6

<< Back Next >>

Med Int Mex 2019; 35 (6)

Pemphigus vulgaris

Medécigo-Hernández JR, Bautista-Sánchez U, Bautista-Ruiz A, Robles-Piedras AL

Language: Spanish
References: 15
Page: 964-968
PDF size: 344.59 Kb.


ABSTRACT

Background: Pemphigus vulgaris is a rare autoimmune disease characterized by blisters on the skin and mucous membranes. It has a worldwide incidence of 0.5 to 32 per 100,000 inhabitants per year, with significant variations between different countries, and is seen most frequently between 50 and 60 years of age. Pemphigus is treated with corticosteroids and azathioprine but in recent years new drugs, such as immunoglobulins and rituximab among others, have been included.
Clinical case: A 42-year-old male patient who presented vesicullary lesions, disseminated and recurrent, with scabs on the head, neck, chest, abdomen and extremities, as well as pharynx with mild hyperemia and afta type lesions, of four months of evolution.
Conclusions: General steroids modify the prognosis of pemphigus, before administration the mortality from pemphigus was 75%, when treatment with steroids began in the 1950s, mortality decreased to 30%; Mortality continued to decline in the following decades to 5.9%, coinciding with the introduction of adjuvant immunosuppressive therapy.


REFERENCES

  1. Chiapa M, Becker I. Pénfigo vulgar: una revisión de la inmunopatología. Bioquimia 2007;32:100-8.

  2. Sánchez-Pérez J, García-Díez A. Pénfigo. Actas Dermosifiliogr 2005;96:329-56. DOI: 10.1016/S0001-7310(05)73090-8.

  3. Meyer N, Misery L. Geoepidemiologic considerations of auto- immune pemphigus. Autoimmun Rev 2010;9(5):A379- 82. doi: 10.1016/j.autrev.2009.10.009.

  4. Tirado Sánchez A, Ponce Olivera RM, Montes de Oca Sánchez G, León Dorantes G. Pénfigo vulgar. Estudio epidemiológico y análisis de posibles factores de riesgo de mortalidad. Dermatol Rev Mex 2006;50:50-3.

  5. Ruocco E, Baroni A, Wolf R, Ruocco V. Life-threatening bullous dermatoses: Pemphigus vulgaris. Clin Dermatol 2005;23:223-6. DOI: 10.1016/j.clindermatol.2004.06.015.

  6. Dagistan S, Goregen M, Miloglu O, Cakur B. Oral pemphigus vulgaris: a case report with review of the literature. J Oral Sci 2008;50:359-62. DOI: 10.2334/josnusd.50.359.

  7. Sirois D, Leigh JE, Sollecito TP. Oral pemphigus vulgaris preceding cutaneous lesions: recognition and diagnosis. J Am Dent Assoc 2000;131:1156-60. DOI: 10.14219/jada. archive.2000.0349.

  8. Gharote HP, Nair PP, Kasetty S, Thomas S, Kulkarni A. Pemphigus vulgaris -a report of three cases. BMJ Case Rep 2012.

  9. Harman KE, Albert S, Black MM; British Association of Dermatologists. Guidelines for the management of pemphigus vulgaris. Br J Dermatol 2003;149:926-37. DOI: 10.1111/j.1365-2133.2003.05665.x.

  10. Ettlin DA. Pemphigus. Dent Clin North Am 2005;49:107-25. DOI: 10.1016/j.cden.2004.08.002.

  11. Femiano F, Gombos F, Scully C. Pemphigus vulgaris with oral involvement: evaluation of two different systemic corticosteroid therapeutic protocols. J Eur Acad Dermatol Venereol 2002;16:353-6. DOI: 10.1046/j.1468-3083.2002.00461.x.

  12. Fellner MJ, Sapadin AN. Current therapy of pemphigus vulgaris. Mt Sinai J Med 2001;68:268-78.

  13. Scully C, Paes De Almeida O, Porter SR, Gilkes JJ. Pemphigus vulgaris: the manifestations and long-term management of 55 patients with oral lesions. Br J Dermatol 1999;140:84-9. DOI: 10.1046/j.1365-2133.1999.02612.x.

  14. Frey FJ. Kinetics and dynamics of prednisolone. Endocr Rev 1987;8:453-73. DOI: 10.1210/edrv-8-4-453.

  15. Cholera M, Chainani-Wu N. Management of pemphigus vulgaris. Adv Ther 2016;33:910-58. doi: 10.1007/s12325- 016-0343-4.




2020     |     www.medigraphic.com